Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note released on Wednesday morning. The brokerage issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a research note on Monday, November 11th.

Cytosorbents Price Performance

Shares of CTSO opened at $0.97 on Wednesday. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $2.15. The company has a market cap of $52.77 million, a price-to-earnings ratio of -2.64 and a beta of 0.57. The company’s fifty day simple moving average is $1.05 and its 200 day simple moving average is $1.02. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Atomi Financial Group Inc. bought a new position in shares of Cytosorbents in the third quarter worth about $51,000. CM Management LLC increased its stake in shares of Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after buying an additional 25,000 shares during the period. Geode Capital Management LLC increased its stake in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares during the period. Finally, Sargent Investment Group LLC increased its stake in shares of Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after buying an additional 67,181 shares during the period. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.